Discover how our AI-driven platform accelerates monoclonal antibody development, reducing costs and timelines.
Axio's AI-powered platform accelerates monoclonal antibody (mAb) development by transforming raw sequence data into actionable insights. Built on a foundation of machine learning, experimental feedback, and bioprocessing expertise, our platform dramatically reduces timelines while improving quality, scalability, and predictability.
Our platform begins with a comprehensive analysis of the amino acid sequence, generating a rich feature set to guide downstream predictions. This enables accurate insights into molecular behavior, stability, solubility, and purification potential—critical for model training and experimental optimization.
Every experiment informs the next. As new data enters the system, the platform retrains and refines itself—continuously improving its accuracy, adaptability, and relevance to your unique molecule.
Run virtual experiments before touching the bench. Simulate purification workflows, stress-test process parameters, and compare design-of-experiment (DoE) outputs—all in silico, all fast.
Trained on historical and in-process experimental data, our AI engine forecasts optimal manufacturing conditions, including resin choice, pH, temperature, and elution strategies. This reduces trial-and-error and cuts process development timelines from years to days.
Already have a manufacturing process in place? Our AI seamlessly integrates to analyze, refine, and enhance your current workflows—identifying cost savings, boosting yield, and flagging hidden risks.
Whether you’re optimizing research-grade batches or scaling up for GMP production, our AI platform adapts to meet your needs. It grows with your molecule—reducing risk from discovery through commercialization.
Our experts design customized manufacturing strategies for your mammalian expressed proteins. We focus on developing robust, scalable processes that meet your specific requirements, ensuring a seamless transition from research-grade to GMP production. By aligning our expertise with your goals, we help streamline your path to success.
Accelerate your early-stage discovery programs with our small-scale parallel manufacturing services. From 96-well plates up to 2 L shake flask expression volumes, we provide rapid, reliable protein production for discovery programs. Our efficient manufacturing offers the agility you need to confidently advance your projects.
We deliver high-quality research-grade protein production to support your R&D efforts. Our scalable solutions ensure consistent, reproducible results, supporting preclinical studies and early-stage development.
With our strategic partners we offer GMP manufacturing services to support clinical development. Services include process validation, large-scale production, and regulatory support, helping you bring life-saving therapies to patients faster.
MKLP1 Pro™ IgM and IgG
Owned by eMBR Genomics, manufactured and distributed exclusively by Axio BioPharma
